Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of nal-IRI-containing regimens versus nab-paclitaxel + gemcitabine in untreated metastatic pancreatic adenocarcinoma
2015-003086-28Phase 2Terminated
- Sponsor
- Merrimack Pharmaceuticals
- Start
- Jun 2016
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nanoliposomal irinotecan, paclitaxel and gemcitabine in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by Merrimack Pharmaceuticals. Primary endpoints: Safety and dose-limiting toxicities, Pharmacokinetics of nal-IRI and metabolites and 1 more. Started Jun 2016; status: terminated.
02
Drugs
nanoliposomal irinotecanpaclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2015-003086-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003086-28.